Scott Webster is the Managing Director of Smithfield Bioscience. He rejoined Smithfield in 2017 and was previously General Manager, Bioscience. In this role he leads the team at the facility in Cincinnati commercializing and manufacturing bioproducts derived from pigs.
Webster is an animal agriculture authority across a broad area of expertise including animal nutrition, pharmaceuticals, live production operations management, supply chain sales and management, and financial decisions throughout the entire animal protein value chain. Earlier in his career, he spent 17 years within Smithfield Foods and legacy company live animal production operations where he progressed through technical and management roles culminating with 7 years as Vice President/General Manager of Production Operations in North Carolina.
Webster has also held multiple roles in the animal feed industry in sales, technical and management roles. He has previous pharmaceutical company experience with Pfizer (now Zoetis) where he provided leadership and implementation experience for the introduction of new technology throughout the USA swine industry.
Mr. Webster grew up on the family farm in Minnesota, was technically trained as a swine nutritionist and maintains certification credentials as a Professional Animal Scientist (PAS) through the American Registry of Professional Animal Scientists. He holds a B.S. in Animal Science with a minor in Agricultural Economics from the University of Minnesota and an M.S. in Animal Science from the University of Missouri.
Dr. Hufnagle joined Smithfield BioScience in his current position in June 2017. Hufnagle leads the quality control, quality assurance and regulatory affairs functions. He has extensive experience in GMP quality systems and facilitating product approvals with global regulatory bodies. Dr. Hufnagle joined Smithfield after five years at a former independent operating company, Celsus Laboratories, where he led the quality assurance and regulatory affairs groups. Hufnagle holds a B.S. in Chemistry from the University of Dayton and a Ph.D. in Analytical Chemistry from Miami University.
Mr. Van Gorp has provided management leadership of the manufacturing operations for Smithfield BioScience’s Heparin Operation since 1996. He has extensive experience in API production and new product development. Van Gorp became plant manager at the Smithfield BioScience facility in 2019. Prior to the acquisition, he spent 21 years at a former independent operating company, Celsus Laboratories, where he managed the production operations for heparin and heparin derivatives, including low molecular weight heparins, ardeparin and enoxaparin. Van Gorp is a foreign war combat veteran of the United States Marine Corps.